Evgen Pharma Share Discussion Threads

[mesquida] 06/4/2021 10:57

Presumably today's volume is also a result of it being the first day of the new tax year, no more tax-loss selling, combined with investors buying to utilise thir new ISA allowance.

[riggerbeautz] 06/4/2021 10:55

They don’t search the internet for sources of relevance or inspiration, more content to wait what is fed them by the hand that pays. Seems like your little gem of a find has got a few people thinking this morning.

[peterm10] 06/4/2021 10:02

Thanks for the posts . Think I posted a few weeks ago and others maybe that Albena D-K is a special advisor to Evgen and is a prof at John Hopkins and the culman chempprotection offshoot . Looking forward to some movement again

[muddy_40] 06/4/2021 09:42

I think that excellent find by bumpa33 could have brought in a few buyers.

Really compelling read

[moneymunch] 06/4/2021 09:39

In a blink of an eye....;-)

[clocktower] 06/4/2021 09:33

Back on the right road, hopefully soon be back in the blue.

[moneymunch] 06/4/2021 07:58

Yep, and John Hopkins University research suggests and near enough validates that Sulforaphane is a promising treatment for Covid-19 and its variants, as well as ARDS and associated Respiratory disease, which has to increase the potent SFX-01's chances of success in treating Covid/ARDS.....the risk/reward now appears firmly in our favour.....let's see if the market has noticed while we await Prof Chalmers preliminary efficacy data from SFX-01's Covid/ARDS patient trials. Gla ;-)

[bumpa33] 05/4/2021 18:46

It all helps Rb, you know how these things can go from ‘no one’ being interested to ‘everyone̵7; in the blink of an eye.

[riggerbeautz] 05/4/2021 14:54

Good to see doing your homework Bumpa, like that conclusion.

[moneymunch] 05/4/2021 13:46

More complelling data for SFX-01's chances of success. Gla ;-)

9/12/20

Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases

Abstract

COVID-19 is described in a clinical case involving a patient who proposed the hypothesis that Nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-interacting nutrients may help to prevent severe COVID-19 symptoms. Capsules of broccoli seeds containing glucoraphanin were being taken before the onset of SARS-CoV-2 infection and were continued daily for over a month after the first COVID-19 symptoms.

They were found to reduce many of the symptoms rapidly and for a duration of 6–12 h by repeated dosing. When the patient was stable but still suffering from cough and nasal obstruction when not taking the broccoli capsules, a double-blind induced cough challenge confirmed the speed of onset of the capsules (less than 10 min).

A second clinical case with lower broccoli doses carried out during the cytokine storm confirmed the clinical benefits already observed. A third clinical case showed similar effects at the onset of symptoms.

In the first clinical trial, we used a dose of under 600 μmol per day of glucoraphanin. However, such a high dose may induce pharmacologic effects that require careful examination before the performance of any study. It is likely that the fast onset of action is mediated through the TRPA1 channel. These experimental clinical cases represent a proof-of-concept confirming the hypothesis that Nrf2-interacting nutrients are effective in COVID-19.

However, this cannot be used in practice before the availability of further safety data, and confirmation is necessary through proper trials on efficacy and safety.

[bocker01] 05/4/2021 12:18

That was a truly excellent article Bumpa. Thanks for sharing it!

[nico115] 05/4/2021 12:04

Is there a correlation between the amount of mm posts and the steepness of our fallTry not to post mm ?

[bumpa33] 05/4/2021 08:54

“The similar results observed between the coronaviruses evaluated suggest that SFN could have broad activity against coronaviruses, a feature that may prove invaluable as new strains of pathogenic coronaviruses enter the human population.”

[moneymunch] 05/4/2021 08:41

We further evaluated SFN for activity against a second reference strain of SARS-CoV-2 as well as two clinical strains that carry the spike D614G (614G+) substitution that is found in the majority of variants of concern currently in circulation (Figure 2D) 9. SFN inhibited USA-WA1/2020, (IC50 = 31 μM, 95% CI 14.7 – 66.4) and the two 614G+ clinical strains, USA/MDHP-20/2020 (MD) and USA/DCHP-7/2020 (DC) (IC50 = 28 μM, 95% CI 14.9 – 52.9, and 29 μM, 95% CI 8.2 – 102.3, respectively), with comparable efficacy to that reported above for reference strain Wuhan-Hu-1.

[moneymunch] 05/4/2021 08:34

Our aim was to interrogate SFN for efficacy against human coronaviruses.

We report here that SFN inhibits in vitro seasonal coronavirus HCoV-OC43 and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections of mammalian host cells and appears to have a synergistic interaction with remdesivir. In addition, SFN reduces viral load and pulmonary pathology in a mouse model of SARS-CoV-2 infection.

[moneymunch] 05/4/2021 08:30

Not peer reviewed yet Bumpa, but published 25th March 2021 by John Hopkins University of Medicine, Baltimore, USA .....the next best thing and home of over 20 years of research into the therapeutic potential of Sulforaphane. Gl ;-)

"Hopkins scientists expand their 20-year mission to understand the disease-deterring benefits of a potent plant compound found in broccoli."

[bumpa33] 04/4/2021 22:27

It’s certainly noteworthy mm - and proves others are making the same connections/joining the same dots and looking for the same conclusions. As the disclaimer at the top says though, these are preliminary reports and not peer reviewed. Maybe I’m underplaying it, all the same - excellent stuff.

[moneymunch] 04/4/2021 21:18

Ps a stunning validation of the risk reward for upside off the scale.:-)

[moneymunch] 04/4/2021 19:50

Boom Time???? ;-)))))

[moneymunch] 04/4/2021 19:45

A great find Bumpa, and incredibly compelling and definitely tips the risk reward firmly in our favour. Gl :-)


Conclusion

We documented that SFN can inhibit the in vitro and in vivo replication of SARS-CoV-2 at pharmacologically and therapeutically achievable doses and can modulate the inflammatory response thereby decreasing the consequences of infection in the animal model when administered prior to infection. Given that SFN is orally bioavailable, commercially available, and has limited side-effects, our results suggest it could be a promising and easily scalable approach for the prevention and treatment of COVID-19 as well as other coronavirus infections.

[bumpa33] 04/4/2021 19:17

more very recent research, apologies if already posted. Not peer reviewed but certainly interesting and relevant.